Now in Korea, the SGLT-2 inhibitor-based type 2 diabetes treatment’Posiga’ can be used to treat chronic heart failure with or without diabetes.
On the 22nd, the Ministry of Food and Drug Safety approved an additional indication for chronic heart failure treatment for AstraZeneca’s Pocigar (ingredient name dapagliflozin).
Depending on the additional indications, Posiga can be used for the treatment of chronic heart failure (HFrEF) patients 18 years of age or older with reduced left ventricular systolic function.
This makes Posiga the first SGLT-2 inhibitor to be used as a treatment for heart failure with or without diabetes.
Heart failure is a disease in which heart failure does not supply the amount of blood necessary for metabolism in the body due to decreased heart function. .
Currently, renin-angiotensin blockers and beta blockers are being used as drugs to improve survival rates, but there is still a large unsatisfactory demand for new drugs.
This additional indication for heart failure treatment was DAPA for 4,744 patients with chronic heart failure (NYHA functional class II~IV) with reduced left ventricular contractile function (left ventricular ejection rate less than 40%) regardless of type 2 diabetes. -It was based on HF research.
About 55% of the subjects were patients without type 2 diabetes, more than 94% of all patients were taking renin-angiotensin blockers, and more than 96% were taking beta blockers.
As a result of the study, Posiga reduced the risk of worsening heart failure and death from cardiovascular disease, the primary endpoint, by 26% compared to placebo. In addition, the risk of death from all causes and cardiovascular death were both reduced by 17% and 18% compared to placebo, respectively.
In particular, in the group of patients without type 2 diabetes, the risk of deteriorating heart failure and death from cardiovascular disease was reduced by 27% compared to placebo, confirming that it is effective for heart failure regardless of diabetes. Posiga’s safety profile was consistent with previous studies.
Il Shim, Managing Director of CVRM Division of AstraZeneca Korea, said, “We are pleased to be able to provide Posiga with a new treatment option that can improve the survival rate of patients with heart failure.” “It will be an important starting point for presenting a milestone for SGLT-2 inhibitors, which are expanding as treatments for heart failure.”